Sanara MedTech Inc. — Earnings Quality Grade F
SMTI · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 42 days, change -10 days YoY
AR growth -3.3% vs revenue growth 19.0%
Revenue 19.0%, CFFO 28634.4%. Cash follows revenue
Expense Quality
Inventory growth 43.4% far exceeds COGS -7.6%, margin rising. Fraud signal
Small-cap context: Inventory ratios on a small base are noisy; a single product launch can move them sharply.
CapEx growth 1927.5% is >2x revenue growth 19.0%
SG&A/Gross Profit = 82.3%, exceeds 70%
Gross margin 92.7%, change +2.1pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF $0.0B, FCF/NI = -0.06
Accruals ratio = -60.8%. Low accruals
Cash $0.0B covers only 34% of debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 375% of equity. Over 50%
Debt/EBITDA = 4.7x (>4x). Interest coverage = 1.4x (<2x). Financial stress
Insufficient data
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
Goodwill+Intangibles change -18% YoY. Normal
Manipulation Score
M-Score = -5.60 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25